

Hai-Xiang Chen,^a Bing Tu,^b Zhan Shu,^b Xing-Jü Ma^b and Zhi-Min Jin^{b*}^aAnalytical Center, Zhejiang Sci-Tech University, Hangzhou 310018, People's Republic of China, and ^bCollege of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310014, People's Republic of China

Correspondence e-mail: apharm@sina.com


Key indicators

Single-crystal X-ray study
 $T = 298$ K
Mean $\sigma(\text{C}-\text{C}) = 0.005$ Å
 R factor = 0.063
 wR factor = 0.167
Data-to-parameter ratio = 12.3For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.7-(1,3-Dioxolan-2-ylmethyl)-1,3-dimethyl-3,7-dihydro-1*H*-purine-2,6-dione

In the title compound, $\text{C}_{11}\text{H}_{14}\text{N}_4\text{O}_4$, doxofylline [7-(1,3-dioxolan-2-ylmethyl)-3,7-dihydro-1,3-dimethyl-1*H*-purine-2,6-dione] molecules are linked by $\text{C}-\text{H}\cdots\text{N}$ hydrogen bonds to form weakly hydrogen-bonded dimers, which are further linked by $\text{C}-\text{H}\cdots\text{O}$ hydrogen bonds to form a three-dimensional network.

Comment

Doxofylline [7-(1,3-dioxolan-2-ylmethyl)-3,7-dihydro-1,3-dimethyl-1*H*-purine-2,6-dione], (I), is a purine alkaloid possessing pharmacological properties. It is used as a therapeutic agent with anti-asthmatic (Franzone *et al.*, 1989) and anti-inflammatory activities (Zhao *et al.*, 2001) and a bronchodilating effect on smooth muscle (Franzone *et al.*, 1981).



In the purine ring system of (I), the $\text{N}3-\text{C}5$ [1.341 (4) Å] and $\text{N}4-\text{C}5$ [1.335 (4) Å] bonds (Table 1 and Fig. 1) are clearly longer than corresponding $\text{C}-\text{N}$ distances in the purine ring of theophylline [1.327 (8) and 1.316 (7) Å, Ebisuzaki *et al.*, 1997]. The other geometric features of the purine ring system of (I) are similar to those in theophylline.

A molecular packing diagram is given in Fig. 2. In the crystal structure, doxofylline molecules are linked by pairs of $\text{C}5-\text{H}5\cdots\text{N}4^i$ hydrogen bonds, forming dimers. The hydrogen-bonding pattern can be described by the graph set $R_2^2(6)$ (Etter, 1990). The dimers are further linked by $\text{C}8-\text{H}8\text{A}\cdots\text{O}2^{\text{ii}}$, $\text{C}8-\text{H}8\text{B}\cdots\text{O}1^{\text{iii}}$ and $\text{C}11-\text{H}11\text{C}\cdots\text{O}2^{\text{iv}}$ hydrogen bonds to form a three-dimensional structure (Table 2).

Experimental

Doxofylline was synthesized according with a published procedure (Li *et al.*, 1995), from theophylline by substitution, oxidation and condensation. It was dissolved in sufficient ethanol by heating to 353 K. Crystals of (I) were formed by gradual evaporation of the ethanol over a period of one week at 293 K.

Received 21 August 2006
Accepted 12 December 2006

Crystal data

$C_{11}H_{14}N_4O_4$
 $M_r = 266.26$
 Monoclinic, $P2_1/c$
 $a = 4.9163(15) \text{ \AA}$
 $b = 20.753(6) \text{ \AA}$
 $c = 11.772(4) \text{ \AA}$
 $\beta = 91.063(6)^\circ$
 $V = 1200.9(6) \text{ \AA}^3$

$Z = 4$
 $D_x = 1.473 \text{ Mg m}^{-3}$
 Mo $K\alpha$ radiation
 $\mu = 0.11 \text{ mm}^{-1}$
 $T = 298(2) \text{ K}$
 Block, colorless
 $0.36 \times 0.24 \times 0.21 \text{ mm}$

Data collection

Bruker APEX area-detector
 diffractometer
 φ and ω scans
 Absorption correction: multi-scan
 (SADABS; Bruker, 2002)
 $T_{\min} = 0.960$, $T_{\max} = 0.981$

6254 measured reflections
 2140 independent reflections
 1642 reflections with $I > 2\sigma(I)$
 $R_{\text{int}} = 0.028$
 $\theta_{\text{max}} = 25.1^\circ$

Refinement

Refinement on F^2
 $R[F^2 > 2\sigma(F^2)] = 0.063$
 $wR(F^2) = 0.167$
 $S = 1.06$
 2140 reflections
 174 parameters
 H-atom parameters constrained

$w = 1/[\sigma^2(F_o^2) + (0.0737P)^2 + 0.6926P]$
 where $P = (F_o^2 + 2F_c^2)/3$
 $(\Delta/\sigma)_{\text{max}} < 0.001$
 $\Delta\rho_{\text{max}} = 0.38 \text{ e \AA}^{-3}$
 $\Delta\rho_{\text{min}} = -0.23 \text{ e \AA}^{-3}$

Table 1

Selected geometric parameters (\AA , $^\circ$).

| | | | |
|----------|-----------|----------|-----------|
| N3—C5 | 1.341 (4) | N4—C5 | 1.335 (4) |
| N3—C4 | 1.384 (3) | N4—C3 | 1.350 (3) |
| N3—C6 | 1.459 (4) | | |
| C5—N3—C4 | 105.4 (2) | C4—N3—C6 | 126.6 (2) |
| C5—N3—C6 | 127.8 (2) | C5—N4—C3 | 103.1 (2) |

Table 2

Hydrogen-bond geometry (\AA , $^\circ$).

| $D-H\cdots A$ | $D-H$ | $H\cdots A$ | $D\cdots A$ | $D-H\cdots A$ |
|------------------------------------|-------|-------------|-------------|---------------|
| C5—H5 \cdots O4 | 0.93 | 2.58 | 3.093 (4) | 115 |
| C5—H5 \cdots N4 ⁱ | 0.93 | 2.51 | 3.260 (4) | 138 |
| C6—H6B \cdots O1 | 0.97 | 2.43 | 3.141 (4) | 130 |
| C8—H8A \cdots O2 ⁱⁱ | 0.97 | 2.56 | 3.420 (4) | 147 |
| C8—H8B \cdots O1 ⁱⁱⁱ | 0.97 | 2.51 | 3.398 (4) | 151 |
| C11—H11A \cdots N4 | 0.96 | 2.49 | 2.931 (3) | 108 |
| C11—H11C \cdots O2 ^{iv} | 0.96 | 2.58 | 3.313 (4) | 134 |

Symmetry codes: (i) $-x + 2, -y + 1, -z + 1$; (ii) $x, y, z - 1$; (iii) $x + 1, -y + \frac{1}{2}, z - \frac{1}{2}$; (iv) $-x + 1, -y + 1, -z + 2$.

All H atoms were placed in calculated positions and allowed to ride on their parent atoms at distances of 0.93 (Csp^2), 0.96 (methyl), 0.97 (methylene) and 0.98 \AA (methine), with $U_{\text{iso}}(\text{H}) = 1.2$ or 1.5 times $U_{\text{eq}}(\text{C})$.

Data collection: SMART (Bruker, 2002); cell refinement: SAINT (Bruker, 2002); data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 1997); program(s) used to refine structure: SHELXL97 (Sheldrick, 1997); molecular graphics: SHELXTL (Bruker, 2002); software used to prepare material for publication: SHELXL97.




Figure 1

The molecular structure of (I) with the atom labeling, showing 40% probability displacement ellipsoids.




Figure 2

Packing diagram of (I). Hydrogen bonds are shown as thin dashed lines.

References

- Bruker (2002). SMART (Version 5.618), SADABS (Version 2.05), SAINT (Version 6.02a) and SHELXTL (Version 6.10). Bruker AXS Inc., Madison, Wisconsin, USA.
- Ebisuzaki, Y., Boyle, P. D. & Smith, J. A. (1997). *Acta Cryst.* **C53**, 777–779.
- Etter, M. C. (1990). *Acc. Chem. Res.* **23**, 120–126.
- Franzone, J. S., Cirillo, R. & Biffignandi, P. (1989). *Eur. J. Pharmacol.* **165**, 269–277.
- Li, C.-H., Luo, Z. & Li, Z.-H. (1995). *Chin. J. Pharm.* **26**, 385–386.
- Franzone, J. S., Reboani, C. & Fonzo, D. (1981). *Farmacol. Sci.* **36**, 201–219.
- Sheldrick, G. M. (1997). SHELXS97 and SHELXL97. Version 97-1. University of Göttingen, Germany.
- Zhao, J. J. & Li, L. (2001). *J. N. Bethune Univ. Med. Sci.* **27**, 646–676.